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Despite the prevalence of alcohol abuse and dependence in the US and Europe, there are only ﬁve approved pharmacotherapies
for alcohol dependence. Moreover, these pharmacotherapeutic options have limited clinical utility. The purpose of this paper is to
presentpertinentliteraturesuggestingthatbothalcoholandtheneurosteroidsinteractattheGABAA receptorcomplexandthatthe
neurosteroid sites on this receptor complex could serve as new targets for the development of novel therapeutics for alcohol abuse.
This paper will also present data collected by our laboratory showing that one neurosteroid in particular, dehydroepiandrosterone
(DHEA), decreases ethanol intake in rats under a variety of conditions. In the process, we will also mention relevant studies from
the literature suggesting that both particular subtypes and subunits of the GABAA receptor play an important role in mediating
the interaction of neurosteroids and ethanol.
1.Introduction
Thesuggestionthatneuroactivesteroidscouldhavepotential
asnewpharmacotherapiesforalcoholabuseanddependence
followed shortly after the discovery that ethanol admin-
istration released speciﬁc neurosteroids. These same data
also directly implicated the endogenous neurosteroids as
potential contributors to the behavioral eﬀects of ethanol
[1, 2]. However, elucidating the interaction between the
neuroactive steroids and ethanol has been especially diﬃcult
because both produce a wide variety of molecular and
behavioral eﬀects and both act at multiple receptors [3, 4].
Complicating matters even further, neurosteroids also have
both genomic and nongenomic eﬀects [4] that are often
only dissociable in terms of their time course. Thus, the
goal of this paper is to present pertinent literature regarding
the interaction of ethanol and the neurosteroids while
also highlighting research from our laboratory suggesting
that one neurosteroid in particular, dehydroepiandrosterone
(DHEA), may be a key to discovering promising new
therapeutics for treating alcohol abuse and dependence. In
this process, we also hope to provide compelling evidence
for the involvement of the GABAA receptor complex and the
role speciﬁc subunits of this complex may play in the eﬀects
of DHEA on ethanol intake.
If there is any doubt that new treatments for alcohol
abuse and dependence are needed, one need only to review
some of the most recent epidemiological data on excessive
alcohol use. In 2009, an estimated 18.6 million persons
aged 12 or older met criteria for alcohol dependence or
abuse, representing 7.4 percent of the US population [5].
Despite the prevalence of this problem, there are only ﬁve
approved pharmacotherapies for alcohol dependence in the
US and Europe [6]. Furthermore, these pharmacotherapeu-
tic options have limited clinical utility. For instance, the
opioid antagonist naltrexone has been shown to have limited2 Advances in Pharmacological Sciences
success apart from individuals with a family history of
alcoholdependence,thosewithanenhancedopioidresponse
to ingestion of alcohol, those who self-report enhanced
alcohol cravings, and individuals with a speciﬁc μ-opioid
receptor polymorphism [7–9]. Acamprosate, a synthetic
homotaurine derivative, has been shown to decrease alco-
hol intake, purportedly via modulation of glutamate [9]
and glycine [10] receptors. However, acamprosate had no
direct eﬀect on recombinant glutamate or glycine receptors
expressed in Xenopus oocytes at low, clinically relevant
concentrations [11], and therefore, the mechanism by which
acamprosate modulates ethanol consumption is still unde-
ﬁned. Experiments involving acamprosate suggest that it is
only fully eﬀective in highly motivated subjects with a “goal
of abstinence” [12] and that the combined experience of
acamprosate with ethanol is necessary for decreasing ethanol
intake [13].
2. Importance of the GABAA System in
the Behavioral Effects of Ethanol
Although a variety of neurotransmitters and signaling path-
wayshavebeenshowntobeinvolvedinthebehavioraleﬀects
of ethanol (e.g., [14–16]), central GABAergic activity is
widelyacceptedtobeoneofthemostimportantcomponents
ofethanol’seﬀectsasaCNSdepressant[17,18].Behaviorally,
this supposition is supported by research showing that
benzodiazepines and barbiturates that positively modulate
the GABAA receptor complex can substitute for ethanol
in drug-discrimination procedures [19, 20]. Electrophys-
iological and genetic techniques have also furthered our
understanding of the interaction between ethanol and the
GABAA receptor complex by showing that it has both
direct and indirect eﬀects on the composition of this
heteropentameric chloride ion channel. For example, in
vitro studies with native and recombinant GABAA receptors
indicate ethanol is able to enhance GABA-mediated currents
at receptors containing a δ subunit (which are found almost
exclusively extrasynaptically in vivo) and at doses of ethanol
consistent with those achieved during typical episodes of
social drinking in humans [18, 21, 22]. Studies with mice
in which the δ subunit has been knocked out have shown
the importance of δ subunit-containing GABAA receptor
complexes in mediating many of the eﬀects of ethanol.
These knockout mice are less sensitive to the anticonvulsant
eﬀects of ethanol, demonstrate a decreased hyperexcitability
during ethanol withdrawal, and show a lower preference
for ethanol compared to wild-type controls. In contrast, δ
subunit knockouts did not diﬀer from controls in ethanol-
induced anxiolysis, ataxia, hypnosis, or hypothermia [23].
Because δ subunits are only found in GABAA receptors
thatalsocontainanα4orα6subunit,theimportanceofthese
α subunit subtypes has been the subject of several investi-
gations and debate. For instance, Hanchar et al. [24]f o u n d
that cerebellar granule neurons from Sprague-Dawley rats
with a naturally occurring mutation in the extrasynaptic α6
subunit (arginine (R) to glutamine (Q) in position 100) had
an enhanced response to ethanol. Speciﬁcally, they reported
an increased tonic current amplitude, tonic current noise,
and spontaneous inhibitory postsynaptic current. However,
using similar methods, Botta et al. [25] found that this
mutation did not increase the sensitivity of GABAA receptors
to ethanol; rather, they reported that ethanol modulated
the currents of these channels indirectly via a presynaptic
mechanism. The importance of the α4 subunit in mediating
the eﬀects of ethanol also remains to be determined, as α4
knockout mice had similar anxiolytic, hypothermic, ataxic,
and hypnotic responses to ethanol compared to wild-type
littermates [26].
In addition to modulating GABAA receptors directly,
ethanol can also modulate them indirectly by altering the
levels of GABA-modulating neurosteroids, such as 3α,5α-
THP (allopregnanolone) and 3α,5α-THDOC (allotetrahy-
drodeoxycorticosterone) [1, 2, 27–29]. These neurosteroids
are currently thought to contribute to the various behavioral
eﬀects of ethanol, including its sedative-hypnotic [30, 31],
anxiolytic [32], and discriminative-stimulus eﬀects [33–35].
For example, a reduction in the levels of 3α,5α-THP and
3α,5α-THDOC by the 5α-reductase inhibitor ﬁnasteride
blocked the acquisition of ethanol drinking and the devel-
opment of ethanol preference in male C57BL/6J mice [36].
In healthy, adult social drinkers, ﬁnasteride also reportedly
decreased the subjective eﬀects of ethanol, leading some
investigatorstospeculatethattheseneuroactivesteroidswere
integral for producing ethanol’s subjective eﬀects [37]. In
rats trained to discriminate ethanol from saline, 10mg/kg
of pregnanolone partially substituted (60%–70% drug-lever
responding) for the discriminative-stimulus eﬀects of 1g/kg
of ethanol subsequent to chronic administration of either
saline or ethanol during adolescence [38]. Similarly, in rats
trained to discriminate 5.6mg/kg of pregnanolone from
saline, 1g/kg of ethanol only partially substituted for this
neurosteroid [39]. Together, these symmetrical discrimi-
nation data indicate that the neurosteroid pregnanolone
has overlapping, but not identical, discriminative-stimulus
eﬀects with ethanol.
In contrast to the partial substitution found with preg-
nanolone, Gurkovskaya and Winsauer [38] demonstrated
that the discriminative-stimulus eﬀects of DHEA, which
comes from a common precursor pregnenolone, were unlike
those of ethanol in rats trained to discriminate 1g/kg of
ethanol from saline. Furthermore, DHEA only modestly
shifted the curve for ethanol-lever responding to the right
when it was administered shortly before varying doses
of ethanol (0.18–1.8g/kg). Bienkowski and Kostowski [33]
also reported a similar ﬁnding in that the sulfated deriva-
tive of DHEA, DHEAS, was ineﬀective at blocking the
discriminative-stimulus eﬀects of ethanol. Thus, the eﬀects
of DHEA on the discriminative-stimulus eﬀects of ethanol
are similar to those of RO15-4513, a partial inverse agonist at
thebenzodiazepinereceptorsite,whichnegativelymodulates
the GABAA receptor complex and has only been shown
to modestly attenuate the subjective eﬀects of ethanol (for
review, see [14]). When these data are considered together,
there seems to be little evidence to suggest that compounds
that negatively modulate the GABAA receptor alter the
discriminative-stimulus eﬀects of ethanol even though theseAdvances in Pharmacological Sciences 3
drugs can attenuate some of the other behavioral eﬀects of
ethanol.
Another mechanism by which ethanol enhances
GABAergic activity indirectly is by increasing presynaptic
GABA release [40–42]. Roberto et al. [42] found that direct
infusion of 44mM ethanol to slices of neurons from the
central amygdala of rats reduced paired-pulse facilitation
and increased the frequency of spontaneous inhibitory
post-synaptic potentials and currents (IPSP/IPSCs), changes
that the investigators concluded were indicative of increased
presynaptic GABA release. In addition, studies have shown
increases in the frequency of miniature ISPCs with 100mM
ethanol in Golgi cells from rat cerebellar slices and 70mM
ethanol in spinal motor neurons [40, 41].
Just as GABAergic activity contributes to ethanol’s CNS
depressant and discriminative-stimulus eﬀects, it is also
thoughttobeintegrallyinvolvedinmediatingthereinforcing
eﬀects of ethanol. This notion has been strongly supported
by studies showing that decreases in GABAA receptor activity
can decrease ethanol intake. More speciﬁcally, GABAA
receptor antagonists as well as inverse agonists at the
benzodiazepine receptor site have been shown to decrease
both ethanol preference and operant responding for ethanol
[43–47]. For example, injection of 2ng of the competitive
GABAA receptorantagonistSR95531directlyintothecentral
nucleus of the amygdala decreased operant responding for
ethanol in male rats, demonstrating a direct link between
GABAA receptor modulation and the reinforcing eﬀects of
ethanol [48]. These results were similar to those with RO15-
4513 [49], which has been shown to decrease ethanol intake
and to antagonize the intoxicating eﬀects of ethanol [45, 50–
52] when administered under an operant schedule of food-
and ethanol-reinforced responding. In addition, RO15-4513
has been shown to reverse the memory-impairing eﬀects of
ethanol [53–55], and this reversal was attributed to both
compounds’interactionwithethanolattheGABAA receptor.
Although ethanol’s eﬀects on the brain are pervasive,
the role of GABA and dopamine in parts of the mesolimbic
dopamine system, such as the ventral tegmental area, central
nucleus of the amygdala, and nucleus accumbens, are of
particular interest with regard to the reinforcing eﬀects
of ethanol. Ikemoto et al. [56] found that dopaminergic
neurons in the anterior and posterior portions of the ventral
tegmental area are diﬀerentially regulated by GABAA recep-
tor modulators, as evidenced by a series of studies in which
rats self-infused the GABAA receptor antagonist picrotoxin
into the anterior, but not posterior, ventral tegmental area.
Conversely, rats self-infused the GABAA receptor agonist
muscimol into the posterior, but not anterior, ventral
tegmental area [56, 57]. This was further clariﬁed in a
microdialysis study by Ding et al. [58], in which they found
that the anterior ventral tegmental area was predominantly
under GABA-mediated tonic inhibitory control, whereas the
posterior tegmental area was predominantly under the con-
trol of dopamine-mediated inhibition. These data, therefore,
suggested that the posterior ventral tegmental area may be
of more importance than the anterior ventral tegmental area
in the reinforcing eﬀects of ethanol. The ventral tegmental
area has direct projections to the nucleus accumbens, an
area of the brain classically associated with the translation
of “motivation to action,” or a link between areas of the
brain associated with reward and those associated with drug
seeking [59]. Furthermore, ethanol consumption in alcohol-
preferring rats has been shown to increase extracellular
dopamine content in the nucleus accumbens [60].
3. Effects of DHEAon GABAA Receptors
The discovery of steroid synthesis in the brain quickly
resulted in numerous studies into the physiological roles of
these “neurosteroids,” with an emphasis on their apparent
nongenomic eﬀects [29, 61–64]. In 1990, Majewska et al.
[65]demonstratedthatthesulfatedformofDHEA(DHEAS)
bound to the GABAA receptor on rat neurosynaptosomes.
Further, they showed that DHEAS binding decreased GABA-
mediated current using a whole-cell voltage-clamp tech-
n i q u e .L eF o l le ta l .[ 66] conﬁrmed these ﬁndings using
a whole-cell voltage-clamp technique in frog pituitary cells
and also determined that 10μM of DHEA and DHEAS were
equally eﬀective at decreasing GABA-induced currents. The
next year, Imamura and Prasad investigated the eﬀects of
DHEA and DHEAS on GABA-mediated chloride inﬂux in
neurosynaptosomes derived from rat cortex, hippocampus,
and cerebellum. These investigators determined the eﬀects
of multiple concentrations of DHEA and DHEAS on GABA-
mediated chloride inﬂux and concluded that DHEAS altered
chloride inﬂux with greater potency than DHEA [67]. Park-
Chung et al. [68] also found a diﬀerence in potency between
DHEA and DHEAS, as 100μM DHEAS was nearly twice as
eﬀective at decreasing GABA-induced current as an equal
concentration of DHEA in Xenopus embryos expressing
α1β2γ2 GABAA receptors.
Because multiple studies have shown that DHEAS is
more potent than DHEA, the binding characteristics of
DHEAS at the GABAA receptor have been more widely
studied and characterized. Studies that have investigated the
putative binding sites for DHEAS suggest that neurosteroids
thatarenegativemodulatorsoftheGABAA receptorcomplex
act at sites distinct from those that are positive modulators.
For some neurosteroids, such as pregnanolone, the addition
of a negatively charged sulfate group changes the GABA-
modulating capacity of the neurosteroid from positive to
negative. Substitution of a hemisuccinate group for the sul-
fate imparts the same eﬀect on modulator activity, indicating
that the negative charge of the compound inﬂuences its
activity [68]. These data support the suggestion that sulfated
and unsulfated steroids modulate GABAA receptor activity
through diﬀerent sites [68, 69]. Unfortunately, similarities
between DHEAS and DHEA binding are unknown, and
additional research will be necessary to clarify these issues.
The binding sites for neurosteroids that positively mod-
ulate the GABAA receptor complex, such as 3α,5α-THP and
THDOC, have been more thoroughly investigated [62, 70,
71]. The results from these studies have indicated that these
steroids act at one of two putative neurosteroid binding sites.
The ﬁrst site is thought to reside within the transmembrane
domains of the α and β subunit interface, whereas the4 Advances in Pharmacological Sciences
second site is thought to reside on the α subunit (for
review, see [70]). The failure of DHEA to attenuate the
pregnanolone-induced disruptions in behavior maintained
under a diﬀerential-reinforcement-of-low-rate schedule [72]
suggests that DHEA binds to a site on the GABAA receptor
separate from pregnanolone. Therefore, DHEA is suspected
to act at a site on the GABAA receptor distinct from the
binding site of sulfated neurosteroids such as DHEAS and
from neurosteroids that are positive modulators of the
GABAA receptor such as pregnanolone.
Despite the diﬀerences in potency between DHEA and
DHEAS, DHEA may have greater clinical utility because
of its capacity to cross the blood-brain barrier. The sulfate
group of DHEAS imparts greater hydrophilicity to the
compound, largely limiting its capacity for diﬀusing into
the central nervous system without ﬁrst being hydrolyzed
to the free steroid [73]. The more lipophilic DHEA crosses
the blood-brain barrier in large amounts, as evidenced by
recent work in this laboratory. In this experiment, adult
male Long-Evans rats were administered 56mg/kg of DHEA
and then sacriﬁced along with vehicle-treated control rats
at time points ranging from 15 minutes to six hours after
injection for brain steroid analysis. Steroids were extracted
using the solid-phase technique established and validated by
Newman et al. [74] and then analyzed using a commercially-
available ELISA (DHEA Saliva ELISA kit, IBL International,
Hamburg, Germany). As shown in Figure 1, DHEA levels in
the hippocampus, hypothalamus, and frontal cortex of the
brain were over twentyfold greater than in vehicle-treated
controls. In fact, ﬁfteen minutes following intraperitoneal
(i.p.) injection, DHEA was present at concentrations shown
by Majewska [61] to negatively modulate the GABAA
receptor.
General support for the behavioral eﬀects of DHEA as
a negative modulator of the GABAA receptor complex comes
fromastudybyAmatoetal.[72],whodemonstratedthatthe
acute eﬀects of DHEA administration on behavior were sim-
ilar to other negative or neutral GABAA modulators under
ad i ﬀerential-reinforcement-of-low-rates (DRL) schedule in
rats. This study compared a variety of positive modulators to
DHEA and the negative modulator β-CCM and the neutral
modulator ﬂumazenil across several dependent measures.
Interestingly,DHEAwassimilartoβ-CCMandﬂumazenilin
producing little or no eﬀect on response rate or the temporal
pattern of responding. These ﬁndings directly contrast with
the eﬀects of the positive modulators ethanol, pregnanolone,
lorazepam, and pentobarbital on behavior maintained under
thesameschedule,asthesedrugsincreasedresponserateand
disrupted the temporal pattern of responding.
ThenegativemodulatorsoftheGABAA receptorcomplex
also contrast with the positive modulators in terms of their
eﬀects on anxiety. For instance, the benzodiazepines and
barbiturates that positively modulate the GABAA receptor
complex typically decrease anxiety in animal models as
indicated by increases in suppressed behavior [78–80], time
spent in open arms of the elevated plus maze [81, 82],
and exploration in the open ﬁeld test [83]. In humans,
benzodiazepines are prescribed clinically as anxiolytics.
Unlike these drugs, the negative modulators such as the beta
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Figure 1: The amount of DHEA (ng/g) present in the hypotha-
lamus, hippocampus, and frontal cortex of rats over a six-hour
time period after a single acute intraperitoneal injection. Adult
male Long-Evans rats received either 56mg/kg of DHEA (n = 6)
or an equal volume of cyclodextrin vehicle (n = 5). A DHEA-
treated subject was sacriﬁced with a vehicle-treated control at 15,
30, 60, 120, and 180 minutes after injection, while the ﬁnal DHEA-
treated subject was sacriﬁced 360 minutes after injection. Brains
were collected, ﬂash frozen, and later dissected using the Glowinski
technique [75]. Steroids were extracted from the hypothalamus,
hippocampus, and frontal cortex of each subject using the solid-
phase extraction method described and validated by Newman et al.
[74]. Brieﬂy, tissue from each region was prepared in an aqueous
matrix and steroids were extracted from each sample using a C18
column primed with ethanol and equilibrated with water. Each
sample was eluted, dried, and resuspended in deionized water, and
DHEA levels were determined using ELISA.
carbolines that are inverse agonists at the benzodiazepine
binding site are anxiogenic [82]. While one would expect all
negative modulators of the GABAA receptor complex to be
anxiogenic, this does not seem to be the case for DHEA as
several studies have demonstrated that DHEA is anxiolytic
in situations involving chronic stress [84–86]. Presumably,
the anxiolytic eﬀects of DHEA can be attributed to its
antiglucocorticoid properties, especially considering most
subjectsunderchronicstresshaveincreasedlevelsofcortisol.
The DHEA/cortisol ratio is of particular signiﬁcance, as
the antiglucocorticoid eﬀects of DHEA are postulated to be
the means by which DHEA was able to reduce depression
in humans [87, 88]. Charney [84] has also suggested that
DHEA may be valuable for reducing the response to stress,
particularly in patients with post-traumatic stress disorder.
In addition to the antiglucocorticoid eﬀects of DHEA,
the capacity of DHEA to modulate the release of other
GABA-modulating neurosteroids may also be involved in its
anxiolytic eﬀects. DHEA administration has been shown to
increase peripheral levels of 3α,5α-THP in postmenopausal
women that received 25mg/day for three months [89]a n d
both peripheral and CNS levels of 3α,5α-THP in femaleAdvances in Pharmacological Sciences 5
rats that received 2mg/kg for 14 consecutive days [90].
Together with the ﬁnding that two weeks of DHEA adminis-
tration decreased central levels of pregnenolone sulfate [91],
another neurosteroid that negatively modulates the GABAA
receptor [64, 66], these data suggest that long-term DHEA
administration may increase overall GABAergic tone despite
its capacity for negatively modulating the GABAA receptor
complex acutely. Whether this is a direct eﬀect of DHEA
or a compensatory response to chronic DHEA remains an
important question that will require further investigation.
As mentioned previously, the ﬁve subunits that comprise
the GABAA receptor complex aﬀect the responsiveness
of these receptors to various endogenous and exogenous
substances such as the neurosteroids and benzodiazepines
[71, 92, 93]. Moreover, the repeated stimulation of GABAA
receptor subtypes can induce changes in the subunits
comprising these receptors. The α4 subunit, for example, has
been shown to be particularly sensitive to changing levels of
neurosteroids [93] and was upregulated following chronic
administration of progesterone (a precursor to 3α,5α-THP)
and following withdrawal of progesterone treatment. This
particular subunit is also of interest because it was upreg-
ulated following chronic treatment with benzodiazepines,
and its expression decreased the sensitivity of the GABAA
receptor complex to benzodiazepines [94]. For this reason,
GABAA receptorscontaininganα4subunitareoftenreferred
to as “benzodiazepine insensitive” receptors. The capacity of
GABAA ligands to modify GABAA receptor subunit expres-
sion is, therefore, another putative mechanism by which
DHEA treatment might alter ethanol intake and preference.
This notion led us to investigate the eﬀect of DHEA
administration on the expression of the α4 subunit of the
GABAA receptor complex. In this study, twenty-four drug-
na¨ ı v em a l eL o n g - E v a n sh o o d e dr a t sr e c e i v e de i t h e r5 6m g / k g
of DHEA (n = 12) or vehicle (n = 12) daily for a ten-day
period.Ontheﬁnaldayoftreatment,subjectsweresacriﬁced
and the brains collected for analysis. Quantitative analysis of
mRNA transcripts indicated that DHEA-treated rats had an
approximately threefold increase in expression of α4 subunit
mRNA in the hypothalamus compared to vehicle-treated
controls, as shown in Figure 2. Interestingly, the expression
of the α4 subunit mRNA in the frontal cortex did not diﬀer
between treatment groups. Together, these data suggested
that the capacity of DHEA to alter α4 subunit expression
is brain-region dependent, and this was further supported
by Western-blot analysis showing that α4 subunit protein
expression was increased in the hypothalamus following
DHEA treatment compared to control (see Figure 3). In
addition, expression of the δ subunit, which is expressed
nearly exclusively in receptor complexes with either the α4
or α6 subunits, was not altered by DHEA treatment. More
studies are certainly warranted to determine the implication
of these ﬁndings.
4.DHEADecreasesEthanolIntake
Working under the hypothesis that negative modulators of
the GABAA receptor complex generally decrease ethanol
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Figure 2: Mean number of GABAA alpha-4 subunit transcript
copies per cell in the hypothalamus (top panel) and frontal cortex
(bottom panel) of rats administered 56mg/kg of DHEA or vehicle.
Drug-na¨ ıve male rats received either DHEA (n = 12) or an equal
volume of cyclodextrin vehicle (n = 12) for ten consecutive days;
on the tenth day, subjects were sacriﬁced and their brains were
collected. Brains were dissected using the Glowinski technique [75],
and each brain region was pooled and homogenized. Due to the
high lipid content of the samples, a spin column technique was
utilized for the RNA extraction. RNA analysis was performed using
TaqMan assay kits (Applied Biosystems, Foster City, Calif, USA).
Approximately 1 to 2μL of each sample were used to determine
the RNA concentration in each sample using Nanodrop. Values are
expressed as a fraction of a normalizing gene, ribosomal 18S RNA.
intake, we initiated a series of studies to determine if DHEA
could produce the same eﬀect. Using a relatively standard
ethanol preference procedure, our ﬁrst study compared the
eﬀects of DHEA and pregnanolone on home-cage ethanol
intake and found that DHEA was more eﬀective at reducing
the intake of an 18% (v/v) ethanol solution than preg-
nanolone [95], which has been shown to positively modulate
the GABAA receptor complex. These results were important
for several reasons. First, they showed that the neurosteroids
remain a relatively unexplored class of drugs with enormous
therapeutic potential. Second, they showed that neuros-
teroids with the capacity to negatively modulate the GABAA6 Advances in Pharmacological Sciences
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Figure 3: Expression of the α4, α3, and δ subunits of GABAA receptors in the hypothalamus of rats administered 56mg/kg of DHEA for 10
consecutive days as measured by Western blot analysis. 100μgo ft i s s u ef r o me a c ha r e aw a sr e s u s p e n d e di nl y s i sb u ﬀe r( 2 0m MT r i sp H8 . 0 ,
137mM NaCl, 0.5mM sodium orthovanadate, 2mM okadaic acid, 10% glycerol, 1% Nonidet P40, 2% protease inhibitor) and processed for
protein extraction using MicroRoto for Lysis Kit (Bio-Rad, Hercules, Calif, USA). The Bradford Method [76] was used to determine protein
concentration, and then samples were diluted, separated by SDS-PAGE, and transferred to nitrocellulose PDVF membranes (Amersham
Biosciences, Piscataway, NJ, USA). The membranes were immunoblotted for two hours at room temperature with two speciﬁc antibodies,
a rabbit anti-α4 antibody at a 1:500 dilution (Santa Cruz Biotechnology, Santa Cruz, Calif, USA), and a mouse anti-β-actin diluted in a
proportionof1:2000(SantaCruzBiotechnology).Aspeciﬁcsecondaryantibody(PerkinElmerLifeSciences,Waltham,Mass,USA)followed
atadilutionof1:2000.ExpressionwasvisualizedusingECLPlus(PerkinElmer)andaFujiFilmluminescentimageanalyzer(LAS-1000Plus,
Fuji Photo Film Co. Ltd., Tokyo, Japan). The images were then quantiﬁed by densitometry using the Image Gauge program [77], and the
expression value of each subunit was normalized to β-actin values.
receptor complex may be as valuable, or more valuable, as
therapeutics for alcohol abuse and dependence than positive
modulators, which could putatively serve as substitution
therapies for alcohol. An important methodological detail in
thisstudywasthatneurosteroidinjectionswereadministered
daily until a criterion for stable ethanol intake was achieved;
namely, each dose of neurosteroid was administered until
ethanol intake did not vary by more than ±20% for 3 days
or for a total of 8 days, in which case the last 3 of those 8
days were used for comparison purposes. This criterion was
largelyinstitutedbecause(1)theintakeoflowconcentrations
of ethanol (or low doses of other self-administered drugs) is
inherently variable, (2) acute administration of a potential
therapeutic may not always be representative of a drug’s
capacity to reduce self-administration, and (3) therapeutics
for drug dependence are generally administered chronically
as opposed to acutely. However, using this criterion raised
several critical questions regarding DHEA’s mechanism of
action. First, were multiple injections necessary to achieve
the eﬀect on ethanol intake, and second, were the decreases
in ethanol intake an eﬀect of DHEA or one of several
metabolites including the sex hormones testosterone and
estradiol?
To address these questions, Worrel et al. [96] admin-
istered 7-keto DHEA, a metabolite of DHEA that is not
metabolized to testosterone or estradiol [97], to the subjects
from the Gurkovskaya et al. [95] preference study and
found that this compound produced eﬀects as large as
DHEA. In fact, while 10mg/kg of 7-keto DHEA produced
an eﬀect comparable to DHEA, 56mg/kg of 7-keto DHEA
produced a larger decrease in ethanol intake than DHEA.
Another important aspect of this study was that 7-keto
DHEA decreased ethanol intake after the initial injection,
whichoccurred15minutespriortothe30-minutepreferenceAdvances in Pharmacological Sciences 7
session when ethanol and water were presented. Together,
these data indicated that a major metabolite of DHEA
might be responsible for the eﬀect of DHEA, metabolism of
DHEA to the sex hormones was not necessary to produce
an eﬀect on ethanol intake, and repeated administration
was not necessary to produce an eﬀect with 7-keto DHEA.
Given the onset of the eﬀect of 7-keto DHEA on ethanol
intake, these data also suggest that a nonsteroidal, rather
than steroidal, mechanism of action might be responsible for
DHEA’s observed eﬀects.
In more recent studies conducted in our laboratory,
we have established ethanol self-administration under an
operant schedule of reinforcement in order to compare the
eﬀects of DHEA (and 7-keto DHEA) on voluntary versus
schedule-controlled ethanol intake. To establish ethanol-
maintained behavior, rats were trained to respond under a
ﬁxed-ratio10scheduleinwhichevery10responsesonalever
dispensed 0.1mL of 18% ethanol to a concave spout located
on the front wall of an operant chamber. After ethanol intake
stabilized under these contingencies, the substitution of
diﬀerent ethanol concentrations was undertaken to compare
the concentration-eﬀect curve for ethanol under the FR-
10 schedule with the curve established under the home-
cage preference procedures. Interestingly, although intake
of the lower concentrations of ethanol was more robust
under the home-cage preference procedure than the operant
procedure, the intake and dose of ethanol between the
two procedures was more similar for the higher ethanol
concentrations. In particular, substitution of a 32% ethanol
concentration for the 18% ethanol concentration produced
similar intake in milliliters and in the dose consumed (see
Figure 4). More important, doses of DHEA that decreased
ethanol intake under the home-cage preference procedure
also decreased ethanol intake under an operant procedure
(e.g., 56mg/kg; Figure 5).
As a means of showing the potential developmental
inﬂuence of DHEA on ethanol preference, we administered
DHEA, lorazepam, or vehicle to three groups of male rats
during adolescence and then assessed preference and intake
of ethanol during adulthood [98]. Lorazepam was included
speciﬁcally as a comparison to DHEA, because it is well
known as a positive allosteric modulator of the GABAA
receptor complex. Brieﬂy, each group of adolescent rats
received a total of 15 injections (12 of one dose and 3 of a
higher dose) on postnatal days (PND) 35–64, and then after
a period of no treatment received 23-hours access to water,
saccharin, or an ethanol/saccharin solution over several days
on two separate occasions (PND 88 and again at PND 111).
On the last occasion, the concentration of ethanol in the
ethanol/saccharin solution was also increased to determine
if the adolescent treatments altered the concentration-eﬀect
curves for each group. In general, this study demonstrated
that lorazepam administration during adolescence increased
adult preference for ethanol compared to vehicle or DHEA
administration, whereas DHEA decreased adult preference
for ethanol and saccharin compared to vehicle administra-
tion. These data were remarkable not only because they
showed the long-term eﬀectof positive allosteric modulation
of GABAA receptors on later, adult ethanol intake, but they
suggest the potential for endogenous levels of DHEA to play
an integral role in shaping adult preference and intake either
through its putative eﬀects on the GABAA receptor complex
or through other as yet unknown mechanisms [98].
5. Summary and Conclusions
Although the exact mechanism by which DHEA decreases
ethanol intake is still under investigation, studies from both
the literature and our laboratory strongly indicate that it
can interact both directly and indirectly with the GABAA
receptor complex and that its behavioral eﬀects are very
similar to those of several other negative GABAA receptor
modulators. Consistent with data generated over the past
several years [21, 22], our data also emphasize the potential
role of extrasynaptic GABAA receptors in the interaction of
the neurosteroid DHEA and alcohol. For instance, recent
electrophysiological and biochemical data have indicated
that GABAA receptors containing a δ subunit are potently
aﬀected by both ethanol and neurosteroids and that these
“extrasynaptic” receptors likely contribute to tonic IPSP and
IPSCsinmanybrainregions.Furthermore,GABAA receptors
with δ subunits are thought to be associated exclusively with
α4andα6subunitsinvivo.Ifthisisthecase,theupregulation
of the α4 subunit could then aﬀect the responsiveness of δ-
containing GABAA receptors, and ultimately, the behavioral
eﬀects of ethanol or the neurosteroids.
Similar to our molecular data pointing to a DHEA-
ethanol interaction, our behavioral studies show that DHEA
can dose dependently decrease ethanol intake in outbred
rats. Interestingly, some of these data were gathered prior
to deﬁnitively knowing whether peripherally administered
DHEA crossed the blood brain barrier and whether DHEA
or one of its hormonal metabolites was responsible for
the eﬀect. Since then, however, we have conducted studies
showing that DHEA readily crosses the blood brain barrier
after peripheral administration (data shown above) and that
metabolism of DHEA to one of the sex hormones (i.e.,
either testosterone or estradiol) is not necessary to obtain the
decrease in ethanol intake [96]. Moreover, we have shown
DHEA can decrease ethanol intake that is voluntary [95]o r
controlled by an operant schedule of reinforcement.
Unfortunately, the eﬀect of DHEA on ethanol intake
cannot be attributed exclusively to its capacity for negatively
modulating GABAA receptor though there is a signiﬁcant
amount of data showing that this capacity may be its most
prominent nongenomic eﬀect [65, 67]. Without question,
the diﬃculty identifying a binding site for DHEA on the
GABAA receptor complex has made the investigation into
DHEA’s mechanism of action more problematic. As indi-
cated in this paper, the binding site for DHEA would seem to
be diﬀerent from the site for sulfated neurosteroids [68, 69]
and from the site for positive GABAA modulators [70]. From
ab e h a v i o r a lp e r s p e c t i v e ,h o w e v e r ,D H E Ap r o d u c e se ﬀects
similar to other negative modulators in rats responding
under at least one operant schedule of reinforcement (i.e.,
a DRL schedule). The most notable exception to DHEA’s
proﬁle as a negative modulator seems to be its capacity for8 Advances in Pharmacological Sciences
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Figure 4: Eﬀects of ethanol concentration on ethanol intake (mL) and the dose of ethanol (g/kg) consumed under home cage (n = 22)
and operant (n = 5) self-administration procedures. Filled circles represent voluntary home cage ethanol intake, whereas unﬁlled circles
represent operant ethanol intake under a ﬁxed ratio (FR) 10 schedule of reinforcement. The points and vertical lines above “W” indicate
the means ± standard error of the mean (SEM) for sessions in which water was available (control). The points with vertical lines in the
concentration-eﬀect data indicate the mean ± SEM for each ethanol concentration. The points without vertical lines indicate instances in
which the SEM is encompassed by the point.
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Figure 5: Eﬀects of intraperitoneal administration of DHEA on rats (n = 5) responding under an FR-10 schedule for 0.1mL of 18% (v/v)
ethanol. The dependent measures were response rate in responses/min and the dose of ethanol presented in g/kg. The points and vertical
lines above “V” indicate the means and standard error of the mean (SEM) for sessions in which vehicle was administered (control). The
points with vertical lines in the dose-eﬀect data indicate the mean ± SEM for sessions in which DHEA was administered. The points without
vertical lines indicate instances in which the SEM is encompassed by the point.
producing anxiolytic, rather than axiogenic, eﬀects [84–86].
This could be viewed as a therapeutic beneﬁt for a medi-
cation that is used to treat alcohol abuse and dependence.
Furthermore, unlike negative modulators such as RO15-
4513,thereisverylittleevidencethatDHEAor7-ketoDHEA
have proconvulsant eﬀects [49, 99]. By contrast, numerous
small clinical trials with DHEA have shown adverse eﬀects
predominantly related to the androgenic eﬀects of DHEA
[100, 101]. For instance, common adverse eﬀects in women
taking 200mg of DHEA per day include acne and hirsutism.
These eﬀects may be averted, however, by administering 7-
keto DHEA, which is not converted to sex hormones [97]
and reduces ethanol intake similarly to DHEA [96].
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